The Leukemia & Lymphoma Society and Celgene have formed a research partnership to gather proposals from academics and smaller biotechs and fund those projects over the next four years. The partnership, which is the society's first with a large biopharma company, will back as many as 10 projects studying disease mechanisms underlying hematological malignancies, and up to two more that aim to develop early-stage clinical candidates or advanced preclinical candidates.

Full Story:

Related Summaries